Entrada Therapeutics, Inc. TRDA · SEC Filings

website

152

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal ...

Price4.69

Market Cap199.41 M

Float28.52 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Entrada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Pipeline Updates

Nov 5, 2026

8-K

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Stu

Oct 14, 2026

8-K

Entrada Therapeutics Reports Second Quarter 2026 Financial Results and Clinical Pipeline Updates

Aug 5, 2026

8-K

Entrada Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 10, 2026

8-K

Entrada Therapeutics Corporate Presentation: DMD and DM1 Clinical Pipeline Update

May 18, 2026

8-K

Entrada Therapeutics Reports First Quarter 2026 Financial Results and Positive Clinical Data for DMD Program

May 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

SHELF OFFERING | Shares amount: 3,367,003 | Share price: $14.85 | Warrants amount: 3,367,003 | Offering amount: $99,999,652.40

Jun 24, 2024

424B5

ATM | Offering amount: $150,000,000

Sep 29, 2023

424B4

OFFERING | Shares amount: 9,075,000 | Share price: $20.00 | Offering amount: $181,500,000.00

Nov 1, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2026

S-3

November 2025 SHELF & ATM

Nov 6, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 25, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2025

S-8

Registration

Mar 13, 2024

S-8

Registration

Mar 6, 2023

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

MPM BioVentures 2014, L.P. (Filed by)

Sep 10, 2026

MPM BIOVENTURES 2018, L.P. (Reporting)

Sep 9, 2026

GADICKE ANSBERT (Reporting)

Sep 9, 2026

MPM BIOVENTURES 2018, L.P. (Reporting)

Sep 3, 2026

GADICKE ANSBERT (Reporting)

Sep 3, 2026

Doshi Dipal (Reporting)

Sep 3, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 4, 2025

CORRESP

Form CORRESP - Correspondence

Dec 1, 2025

LETTER

Form UPLOAD - SEC-generated letter

Dec 20, 2023

CORRESP

Form CORRESP - Correspondence

Dec 6, 2023

LETTER

Form UPLOAD - SEC-generated letter

Nov 21, 2023

CORRESP

Form CORRESP - Correspondence

Nov 13, 2023